Radiopharm Theranostics Future Growth
Future criteria checks 2/6
Radiopharm Theranostics is forecast to grow earnings and revenue by 28.5% and 63.2% per annum respectively. EPS is expected to grow by 35.9% per annum. Return on equity is forecast to be -42.3% in 3 years.
Key information
28.5%
Earnings growth rate
35.9%
EPS growth rate
| Biotechs earnings growth | 16.0% |
| Revenue growth rate | 63.2% |
| Future return on equity | -42.3% |
| Analyst coverage | Low |
| Last updated | 04 Jun 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2026 | 4 | -56 | -21 | -28 | 3 |
| 6/30/2025 | N/A | -48 | -29 | -30 | 3 |
| 6/30/2024 | 0 | -44 | 12 | -19 | 3 |
| 12/31/2023 | 6 | -47 | -24 | -23 | N/A |
| 9/30/2023 | 6 | -41 | -25 | -23 | N/A |
| 6/30/2023 | 6 | -35 | -25 | -23 | N/A |
| 3/31/2023 | 5 | -30 | -21 | -20 | N/A |
| 12/31/2022 | 4 | -26 | -18 | -17 | N/A |
| 9/30/2022 | 2 | -28 | -28 | -14 | N/A |
| 6/30/2022 | N/A | -30 | -38 | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RAD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RAD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RAD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RAD's revenue (63.2% per year) is forecast to grow faster than the Australian market (5.4% per year).
High Growth Revenue: RAD's revenue (63.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RAD is forecast to be unprofitable in 3 years.